Trial Profile

A Phase II/III Study of ICP-248 in Combination with Orelabrutinib in Patients with Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Jun 2025 According to an InnoCare Pharma media release, the data from this study has been presented at the European Hematology Association (EHA) 2025 Congress
13 Jun 2025 Results(n=42) presented in an InnoCare Pharma media release.
28 Mar 2025 According to an InnoCare Pharma media release, company announced that the first patient has been dosed in the Phase III registrational trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 (Mesutoclax) in combination with BTK inhibitor orelabrutinib as a first-line therapy for patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in China

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com